Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 72162-1599

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 72162-1599). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of Duloxetine Hydrochloride, displaying its molecular framework including aromatic rings and heteroatoms characteristic of this active ingredient.*

FDA Label Image

Figure 1 (Duloxetine 02)

A Kaplan-Meier curve graph showing the proportion of patients with relapse over time, comparing placebo treatment and Duloxetine delayed-release capsules. The x-axis represents time while the y-axis shows the proportion of patients with relapse, illustrating relapse rates for each treatment group.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier curve chart illustrating the proportion of patients with relapse over time in days from randomization. It compares relapse rates between placebo and duloxetine delayed-release capsules, showing lower relapse proportions for duloxetine over the observed period up to 300 days.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. Four lines represent different treatment groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg once daily (QD), and placebo. The graph illustrates comparative patient improvement across these groups.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine Hydrochloride 60 mg twice daily (DUL 60mg BID), Duloxetine 60 mg once daily (DUL 60mg QD), and placebo, showing trends in patient improvement levels over a range of pain improvement percentages.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line chart showing the percentage of patients improved versus percent improvement in pain from baseline. The chart compares Duloxetine Delayed-Release 60 mg taken twice daily, once daily, and placebo groups across different levels of pain improvement, illustrating relative performance in pain reduction.*

FDA Label Image

Figure 6 (Duloxetine 07)

Line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine Hydrochloride at doses of 120 mg, 60 mg, 20 mg once daily, and placebo. The graph compares pain improvement outcomes across these different treatment groups over a range of improvement percentages.*

FDA Label Image

Figure 7 (Duloxetine 08)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. Two lines represent Duloxetine delayed-release 60 mg once daily and placebo. The graph shows higher patient improvement percentages for the duloxetine group across pain improvement levels.*

FDA Label Image

Figure 8 (Duloxetine 09)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares two groups: placebo and Duloxetine (DUL) 60/120 mg once daily, illustrating patient response to treatment over various levels of pain improvement.*

FDA Label Image

Figure 9 (Duloxetine 10)

A line graph displaying the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares two groups: one receiving placebo and the other receiving Duloxetine 60 mg once daily, showing a trend of higher patient improvement with Duloxetine.*

FDA Label Image

Figure 10 (Duloxetine 11)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine Delayed-Release 60 mg/120 mg once daily and placebo. The graph shows two lines indicating patient improvement rates at various pain improvement thresholds.*

FDA Label Image

Label (Lbl721621599)

Label for Duloxetine Delayed-Release Capsules, USP 60 mg, containing 90 capsules. The product, with NDC 72162-1599, is labeled by Bryant Ranch Prepack and manufactured by Towa Pharmaceutical Europe, S.L. Storage instructions and a medication guide URL are included on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.